Primary desmoplastic small round cell tumor of the duodenum by Qi Liu et al.
EUROPEAN JOURNAL 
OF MEDICAL RESEARCH
Liu et al. European Journal of Medical Research 2014, 19:38
http://www.eurjmedres.com/content/19/1/38CASE REPORT Open AccessPrimary desmoplastic small round cell tumor of
the duodenum
Qi Liu, Nan Liu and DeXing Chen*Abstract
The desmoplastic small round cell tumor (DSRCT) is an extremely rare tumor that mainly affects adolescents
and mostly involves the abdominal and pelvic peritoneum. A 14-year-old girl presented with intermittent
epigastric pain; abdominal computed tomography and upper gastrointestinal barium X-ray revealed an 8 cm× 10 cm
space-occupying mass in the duodenal region. The patient underwent pancreaticoduodenectomy and the final
pathologic diagnosis was DSRCT. Although multi-agent systemic chemotherapy was given, the patient died of
metastasis 8 months later. Early diagnosis and surgical treatment with adjuvant chemotherapy seems to be
the best treatment choice for this disease.
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The desmoplastic small round cell tumor (DSRCT) is a
rare, aggressive, and malignant tumor, first described by
Gerald in 1989 [1]. It mainly affects adolescents and
mostly involves the abdominal or pelvic peritoneum.
Diagnosis is usually based on the tumor’s histological
and immunohistochemical features. Despite multimo-
dality treatments, DSRCT has a poor prognosis. To the
best of our knowledge, only one case of duodenal DSRCT
has been reported in the English-language literature [2],
making this case the second case to be reported in the
duodenal region so far.Case presentation
On 13 February 2008, a 14-year-old girl presented with a
history of intermittent epigastric pain and bloody vomit
for one month. There was no history of fever, weight loss,
or jaundice. Further examination showed tenderness in
the otherwise soft upper quadrant of the abdomen, with-
out palpable masses. The patient was diagnosed with
chronic cholecystitis and treated with antibiotics for a
week without relief. Hemoglobin concentration and red
blood cell count were 55 g/l, 2.92 × 1012 /l, respectively,
while the concentration of carbohydrate antigen 19-9 was
within normal range. Abdominal ultrasonography revealed* Correspondence: 797980@sina.com
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unless otherwise stated.a 7.1 cm × 7.2 cm hypoechoic mass around the duodenum
and pancreas (Figure 1). Computed tomography (CT) also
detected an 8 cm× 10 cm lobulated solitary mass encirc-
ling the duodenum, with low attenuation and inhomogen-
eous enhancement (Figure 2). There was no evidence of
metastasis to local or distant organs. An upper gastro-
intestinal barium X-ray revealed a defect in the duodenum
and a space-occupying mass, invading retroperitoneally
with a tendency to displace the duodenum (Figure 3). The
patient refused duodenoscopy and was diagnosed as hav-
ing a duodenal tumor before surgery. On surgery, we
found a solid and irregular mass about 10 cm× 8 cm ×
8 cm in the wall of duodenum without complete capsule.
A frozen biopsy was performed and revealed malignant
tumor features similar to malignant lymphoma or undif-
ferentiated malignant tumor, but failed to identify the spe-
cific type or origin of the tumor. The tumor originated
from the descending part of duodenum, and then invaded
the pancreatic caput, gallbladder, and multiple para-aortic
lymph nodes. A pancreaticoduodenectomy was performed
to remove part of the duodenum, the gallbladder, and ad-
jacent lymph nodes. The patient was discharged from hos-
pital 10 days later with an uneventful recovery.
Postoperative examination of the specimen showed a
tumor 8 cm × 10 cm in diameter. The tumor consisted
of nests of ‘small blue cells’ with scant cytoplasm em-
bedded in a densely fibrotic stroma and focal tubule for-
mation. There were also nests of hyperchromatic roundThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Sonography revealed a 7.1 cm × 7.2 cm hypoechoic
mass at the wall of the duodenum and pancreas (arrow).
Figure 3 Upper gastrointestinal barium X-ray revealed a defect
in the duodenum with a tendency to displace the duodenum
(arrow).
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background. Some cells were arranged in well-defined
nests, which were delimited by a cellular desmoplastic
stroma (Figure 4). Immunohistochemical findings showed
that the tumor cells were diffusively positive for vimentin
and CD99 antigen. Focal reactivity to neuron-specific eno-
lase and keratin were observed (Figures 5,6), while tests
for carcinoembryonic antigen, epithelial membrane anti-
gen, and cytokeratin proved negative. Histological and im-
munohistochemical findings confirmed the diagnosis of
DSRCT.
Eight weeks later, the patient was readmitted with nau-
sea and vomiting. Abdominal color Doppler flow imaging
showed a 7.4 cm × 6.7 cm irregular-echo mass with rich a
blood supply. The patient was then treated with two-stage
multi-agent chemotherapy. The longest diameter of theFigure 2 Abdominal computed tomography (CT) showed
an 8 cm × 10 cm lobulated solitary mass encircling the
duodenum with low attenuation and inhomogeneous
enhancement (arrow).
Figure 4 Immunohistochemistry reveals nests of hyperchromatic
round and focally spindle-shaped tumor cells in a desmoplastic
background. Some cells are arranged in well-defined nests, which are
delimited by a cellular desmoplastic stroma (H & E, 200×).
Figure 5 Tumor cells stain positive for neuron-specific
enolase. (200×).
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and duoxitasai. Continued chemotherapy was performed
every three weeks in two cycles after the patient’s release
from hospital. However, the tumor was not sensitive to
the chemotherapy and the patient’s condition deteriorated
progressively; she died of multi-organ metastasis 6 months
later.
Discussion
The DSRCT is a rare and highly malignant tumor. Its
growth is multinodular, involving serosal surfaces, such
as the peritoneum, pleura, tunica vaginalis, and scrotum.
Morphologically, DSRCTs are characterized by the for-
mation of nests of small round cells proliferating in a
cellular fibrous stroma. The DSRCT belongs to the family
of ‘small round blue cell tumors’; nevertheless, molecular
biology has proved that DSRCT is a unique tumor, which
is different from other types of small round cell tumor.
The genetic characterization of DSRCT is a chromosomal
translocation of t(11; 22) (p13;q12) between the Ewing’sFigure 6 Tumor cells stain positive for keratin. (200×).sarcoma (EWS) gene on chromosome 22 and the Wilms’
tumor (WT1) gene on chromosome 11, leading to a
EWS-WT1 fusion transcript. The characteristic transloca-
tion t(11;22) (p13;q12) is specific for DSRCTs. This fusion
product causes a loss of the tumor suppressor function of
WT1 and a putative upregulation of various families of
growth factors from the EWS gene [3]. The differential
diagnosis includes other small round cell tumors, such as
metastatic neuroblastoma, Ewing’s sarcoma, small cell car-
cinoma, and lymphoma, rhabdoid tumor, and small cell
osteosarcoma. The presence of perinuclear dot-like immu-
nostaining with desmin strongly suggests DSRCT [4].
Typical cases of DSRCT in the intra-abdominal cavity
or gastrointestinal tract are accompanied by abdominal
mass or pain, similar to other gastrointestinal tumors.
The most useful radiographic method is CT with intra-
venous contrast. Imaging typically reveals multiple low-
attenuation peritoneal soft tissue with a regular contour.
Most masses are located within the mesentery, omentum,
and paracolic gutter or along abdominopelvic peritoneal
surfaces. Sometimes the lymph nodes and retroperito-
neum can be involved but this is not typical in DSRCT.
Ascites and solitary to multiple metastases nodules can
also present in some patients. Tumors without an appar-
ent primary organ-based distribution can be very suspi-
cious for DSRCT. Currently, the prognosis of DSRCT is
still poor because of its highly aggressive and progressive
malignant character, together with multifocal presentation.
The optimal treatment remains to be determined.
Total surgical excision is recommended only for non-
metastatic DSRCTs. However, complete resection is usu-
ally impossible at an advanced stage [5], and postoperative
systemic adjuvant chemotherapy should be initiated as
soon as possible. Aggressive surgical resection combined
with multi-agent adjuvant chemotherapy can relieve symp-
toms and improve the outcome of advanced DSRCTs.
Unfortunately, most chemotherapy agents are only tem-
porarily effective [6]. Although Farhat et al. recommended
cisplatin, etoposide, cyclophosphamide, doxorubicin, or
epirubicin as first-line alternative drugs, no consistent
responses to chemotherapy are reported [7].
Despite aggressive treatment, the survival rate remains
disappointing. According to a literature review and our
experience, we recommend surgical debulking followed
by aggressive chemotherapy for DSRCT. The correlation
between intense chemotherapy combined with gross total
resection and prolonged lifespan is high. Radiotherapy is
only recommended for salvage therapy, but not for normal
treatment, since the isolation may have less impact and
effectiveness. Moreover, side effects may outweigh treat-
ment. For these advanced-stage patients, symptomatic
treatment is more practical as it alleviates acute dis-
comfort; however, it still leads to a poor outcome. Aggres-
sive multimodality therapy with immunotherapy or bone
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autologous peripheral blood stem cell support may have
potential benefit for DSRCTs and may be a promising new
approach [8]. Recently, continuous hyperthermic periton-
eal perfusion at the time of complete tumor resection has
been developed as an adjunct to treat DSRCTs; this may
prolong disease-free survival in selected cases [9].
Conclusions
We described a second case of DSRCT at the duodenal
region. After tumor surgical ablation, the patient re-
ceived multi-agent systemic chemotherapy, but she died
of multiple metastases some months later. The dismal
prognosis of DSRCT at the duodenal region is similar to
that of DSRCT at the abdominopelvic region. According
to a literature review and our experience, surgical debul-
king followed by aggressive chemotherapy is still the
best treatment for DSRCT, mainly in non-metastatic tu-
mors. However, the optimal treatment remains to be de-
termined for this aggressive tumor.
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